SML3385

Binimetinib

≥98% (HPLC)

• Synonym(e): 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162
• Empirische Formel (Hill-System): C₁₇H₁₅BrF₂N₄O₃
• CAS-Nummer: 606143-89-9
• Molekulargewicht: 441.23
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD22124525
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: O=C(C1=C(C(F)=C(C2=C1)N=CN2C)NC3=C(C=C(C=C3)Br)F)NOCCO
• InChI: 1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
• InChI key: ACWZRVQXLIRSDF-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

Binimetinib (MEK162, ARRY-162) is an orally active, potent, ATP-uncompetitive MEK1/2 inhibitor (IC50 = 12 nM) that inhibits multiple human tumor growth in xenograft mice in vivo regardless of Kras or Braf mutation (30 or 100 mg/kg/day, 100 mg/kg b.i.d.).

Orally active, potent, ATP-uncompetitive MEK1/2 inhibitor that inhibits multiple human tumor growth in vivo regardless of Kras or Braf mutation.

Sicherheitshinweise

• pictograms: GHS09
• hcodes: H411
• pcodes: P273 - P391 - P501
• Hazard Classifications: Aquatic Chronic 2
• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable